Pediatric multiple sclerosis (POMS) is a rare but particularly challenging form of the disease. Children and adolescents with MS often experience more relapses, a greater lesion burden on MRI and early-onset cognitive impairment. At the same time, their long-term course is characterized by a delayed but ultimately unstoppable accumulation of disability. For a long time, therapeutic care was limited and restricted to low to moderately effective therapies. In recent years, however, there has been a paradigm shift: highly effective therapies (HETs) are increasingly being used in pediatric patients – with clear benefits for relapse rate, MRI activity and disease progression.
Autoren
- Tanja Schliebe
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- From early intervention to individualization
The new guidelines at a glance
- Artificial intelligence
Dr. ChatGPT: Large language models in everyday clinical practice
- COPD therapy
Drug therapy – Update 2025
- Focus on prevention
Colorectal cancer screening – an update
- From symptom to diagnosis
Oncology – Thymoma
- Shared decision making
Participatory decision-making using the example of diets for type 1 diabetes
- Patient-centered rounds in medicine
Aligning care with the patient
- Migraine and vascular regulation